# A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

> **NCT00391222** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 585 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** Olanzapine
- **DRUG:** Placebo
- **DRUG:** Risperidone Long Acting Injectable (LAI)

## Key facts

- **NCT ID:** NCT00391222
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 585 (ACTUAL)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00391222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00391222, "A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00391222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*